Разумевање односа између МРД и ЦАР Т-ћелијске терапије
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Терапија мезенхималним матичним ћелијама код неуролошких поремећаја
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
Ознаку лека сирочад даје ФДА ЦАРТ Т-Целл Тхерапи А2Б530 за лечење колоректалног карцинома
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Иованцеов Амтагви је одобрен од стране УСФДА као прва терапија Т-ћелија за солидни тумор
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Амивантамаб-вмјв је одобрен од стране УСФДА за индикације рака плућа не-малих ћелија са мутираним уметањем ексона 20 ЕГФР
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Осимертиниб са хемотерапијом је одобрен од стране УСФДА за ЕГФР-мутирани рак плућа не-малих ћелија
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Лифилеуцел је одобрен од стране УСФДА за неоперабилан или метастатски меланом
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Тепотиниб је одобрен од стране УСФДА за метастатски карцином плућа не-малих ћелија
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Иринотекан липозом је одобрен од стране УСФДА за лечење прве линије метастатског аденокарцинома панкреаса
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Ердафитиниб је одобрен од стране УСФДА за локално узнапредовали или метастатски уротелни карцином
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..